Genetic and Spatial Heterogeneity in Human Papillomavirus-Associated Oropharyngeal Cancer
Joseph Powell will discuss how heterogeneous subpopulations of HPV+ head and neck cancer cells drive unique disease states, cell-cell interactions, and microenvironment dynamics, and have... (Source: The Scientist)
Source: The Scientist - August 20, 2020 Category: Science Tags: Sponsored Webinars Source Type: news
Persistent Hair Loss After Radiation Improved With Minoxidil Persistent Hair Loss After Radiation Improved With Minoxidil
For the first time, a study shows that persistent hair loss after radiotherapy for CNS or head and neck cancer improved with topical minoxidil.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 13, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Roche provides update on Phase III study of Tecentriq in combination with paclitaxel for people with metastatic triple-negative breast cancer
Basel, 06 August 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpassion131 study, evaluating Tecentriq® (atezolizumab) in combination with paclitaxel (chemotherapy), in comparison to placebo plus paclitaxel, did not meet statistical significance on its primary endpoint of progression-fr ee survival (PFS) for the initial (first-line) treatment of people with metastatic triple-negative breast cancer (TNBC), in the PD-L1-positive population. The data for the secondary endpoint of overall survival (OS) showed a negative trend, however, the study was not powered for the secondary endpoint of O...
Source: Roche Investor Update - August 6, 2020 Category: Pharmaceuticals Source Type: news
Roche provides update on Phase III study of Tecentriq in combination with paclitaxel for people with metastatic triple-negative breast cancer
Basel, 06 August 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpassion131 study, evaluating Tecentriq® (atezolizumab) in combination with paclitaxel (chemotherapy), in comparison to placebo plus paclitaxel, did not meet statistical significance on its primary endpoint of progression-fr ee survival (PFS) for the initial (first-line) treatment of people with metastatic triple-negative breast cancer (TNBC), in the PD-L1-positive population. The data for the secondary endpoint of overall survival (OS) showed a negative trend, however, the study was not powered for the secondary endpoint of O...
Source: Roche Media News - August 6, 2020 Category: Pharmaceuticals Source Type: news
Study: Topical minoxidil reverses hair loss caused by radiation for brain, head, neck cancers
Treatment with topical minoxidil helps restore hair loss caused by radiation treatment for brain tumors and other head and neck cancers, a study published Wednesday by JAMA Dermatology found. (Source: Health News - UPI.com)
Source: Health News - UPI.com - August 5, 2020 Category: Consumer Health News Source Type: news
Characteristics, treatment of radiation-induced hair loss in cancer patients
(JAMA Network) Characteristics and response to treatment of persistent radiation-induced hair loss in patients with primary central nervous system tumors or head and neck cancer were examined in this observational study. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 5, 2020 Category: Cancer & Oncology Source Type: news
A normal DNA repair process can become a major source of mutations in cancer
(Institute for Research in Biomedicine (IRB Barcelona)) The mechanism unveiled triggers a mutation fog, causing hundreds of mutations in each tumor, which spread through the genome of lung, head-and-neck and breast cancers.Researchers from the Genome Data Science Lab have identified the antiviral APOBEC3A enzyme as the major cause of this new type of hypermutation.Published in Nature Genetics, the study shows how the mutation fog process generates many oncogenic " cancer driver " mutations, thus accelerating tumour development. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 4, 2020 Category: Cancer & Oncology Source Type: news
FDA approves Roche ’s Tecentriq plus Cotellic and Zelboraf for people with advanced melanoma
Basel, 31 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq ® (atezolizumab) plus Cotellic® (cobimetinib) and Zelboraf® (vemurafenib) for the treatment of BRAF V600 mutation-positive advanced melanoma patients. The safety profile observed in the Tecentriq combination was consistent with the known safety profiles of the individual medicines. The supplemental Biologics License Application (sBLA) for Tecentriq was granted under priority review. The review was also conducted under Project Orbis, an initiative of the FDA Oncology Center of ...
Source: Roche Investor Update - July 31, 2020 Category: Pharmaceuticals Source Type: news
FDA approves Roche ’s Tecentriq plus Cotellic and Zelboraf for people with advanced melanoma
Basel, 31 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq ® (atezolizumab) plus Cotellic® (cobimetinib) and Zelboraf® (vemurafenib) for the treatment of BRAF V600 mutation-positive advanced melanoma patients. The safety profile observed in the Tecentriq combination was consistent with the known safety profiles of the individual medicines. The supplemental Biologics License Application (sBLA) for Tecentriq was granted under priority review. The review was also conducted under Project Orbis, an initiative of the FDA Oncology Center of ...
Source: Roche Media News - July 31, 2020 Category: Pharmaceuticals Source Type: news
Precision medicine identifies key recurring mutation in head and neck cancers
(University of California - San Diego) Researchers at UC San Diego School of Medicine and Moores Cancer Center report that an investigational drug candidate called tipifarnib showed promise in treating key recurring mutation in head and neck cancers. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - July 30, 2020 Category: Biology Source Type: news
Best practice in reducing the suicide risk in head and neck cancer patients: a structured review - Twigg JA, Anderson JM, Humphris G, Nixon I, Rogers SN, Kanatas A.
The treatment of head and neck cancer (HNC) is often radical and the patient's journey challenging, especially for individuals who are struggling with pre-existing mental health problems and who lack social support. Patients frequently suffer from high lev... (Source: SafetyLit)
Source: SafetyLit - July 22, 2020 Category: International Medicine & Public Health Tags: Research Methods, Surveillance and Codes, Models Source Type: news
Researchers ID new target in drive to improve immunotherapy for cancer
FINDINGSResearchers at the UCLA Jonsson Comprehensive Cancer Center and UCLA School of Dentistry have identified a potential new combination therapy to treat advanced head and neck squamous cell carcinoma, the most common type of head and neck cancer.A study in mice found that using an anti-PD1 immunotherapy drug in combination with PTC209, an inhibitor that targets the protein BMI1, successfully stopped the growth and spread of the cancer, prevented reoccurrences and eliminated cancer stem cells. This is the first preclinical study to provide evidence that targeting BMI1 proteins enhances immunotherapy and eliminates ca...
Source: UCLA Newsroom: Health Sciences - July 21, 2020 Category: Universities & Medical Training Source Type: news
Researchers ID new target in drive to improve immunotherapy for cancer
(University of California - Los Angeles Health Sciences) UCLA researchers have identified a potential new combination therapy to treat advanced head and neck squamous cell carcinoma, the most common type of head and neck cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 21, 2020 Category: Cancer & Oncology Source Type: news
Roche provides update on Phase III study of Tecentriq in women with advanced stage ovarian cancer
Basel, 13 July 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMagyn050 study showed that the addition of Tecentriq® (atezolizumab) to Avastin® (bevacizumab), paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival (PFS) for the front-line treatment of women with newly diagnosed advanced stage ovarian cancer. Topline safety data indicate that safety for Tecentriq in combination with Avastin, paclitaxel and carboplatin was consistent with the known safety profile of the combination.“Ovarian cancer remains one of the most aggressive cancers and is difficul...
Source: Roche Investor Update - July 13, 2020 Category: Pharmaceuticals Source Type: news
Roche provides update on Phase III study of Tecentriq in women with advanced stage ovarian cancer
Basel, 13 July 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMagyn050 study showed that the addition of Tecentriq® (atezolizumab) to Avastin® (bevacizumab), paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival (PFS) for the front-line treatment of women with newly diagnosed advanced stage ovarian cancer. Topline safety data indicate that safety for Tecentriq in combination with Avastin, paclitaxel and carboplatin was consistent with the known safety profile of the combination.“Ovarian cancer remains one of the most aggressive cancers and is difficul...
Source: Roche Media News - July 13, 2020 Category: Pharmaceuticals Source Type: news
